Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (379)	5/3/2002 12:08:50 PM
From: nigel bates	Read Replies (1) \| Respond to of 1022

An attempt at a timeline for MEDX (selected highlights only <g>). What strikes me is that they have surprisingly little to show for some pretty heavyweight alliances which date back several years. I have left out an awful lot of deals, many of which are with smaller companies. Pre 1997 Leukosite, Centeon (later acquired by Aventis ?) 1997 Kirin (TC Mouse deal), Centocor (deal to generate mAbs to 4 antigens) 1998 Feb Schering (to generate mAb to a proprietory antigen) June BMY (multiple antigen deal) Nov Novartis (10yr Global unlimited technology license) Nov Centeon (milestone on MDX-33 P1 results for ITP) 1999 Jan IMNX Jan Centocor (milestone on mAb to IL-12) Feb LKST (expanded agreement) May Schering (expanded agreement) Sept AMGN Nov Novartis (technology acess fee) 2000 Jan Kirin (strategic alliance) May J&J/Centocor (technology deal -unlimited no. of mAbs) June MEDI June Biosite (Transphage tech. deal) Sept OGSI Nov Lilly (MEDX to generate mAbs) Dec 'UltimAb' tech. announced Dec Aventis (announce +ve P11 results for MDX-33 in ITP) 2001 Jan Lilly (Transphage tech. deal) Feb J&J/Centocor (IND on first mAb developed thru MEDX technology) Mar Schering (UltimAb collaboration) June HGSI Oct INCY Excepting the IDM and Genmab antibodies (I have deliberately left them off the above list), MEDX has only two mAbs in the clinic partnered with/outlicenced to independent companies - MDX-33 for ITP, which results from a collaboration dating back before 1997, and is apparently still in P11, and a mAb resulting from the Centocor alliance in PI trials for an "undisclosed" anti-inflammatory indication.

To: Icebrg who wrote (379)	5/13/2002 7:15:53 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

Genmab and ACE BioSciences Collaborate to Treat Infectious Disease Genmab and the Danish privately owned ACE BioSciences have entered an alliance to develop new antibody therapeutic products for the treatment of infectious diseases. The companies will share development costs and revenues generated from out-licensing or sales of potential products COPENHAGEN, Denmark, May 13 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN and Neuer Markt: GE9D) and the privately owned Danish based ACE BioSciences announced today a collaboration to develop new antibody products to treat infectious disease. Under the agreement ACE BioSciences will provide novel commercially promising disease targets and Genmab will use the company's fully human antibody technology to create and develop new products. The alliance covers four disease targets in the area of infectious diseases. This marks a new area of operation for Genmab, which until now has concentrated on developing antibodies to treat inflammatory diseases and cancer. The collaboration brings together ACE Biosciences expertise in finding novel infectious disease targets with Genmab's broad antibody development capabilities and extensive array of pre-clinical tools to generate and characterize fully human antibodies. Furthermore the collaboration will utilize the combination of Genmab's anti body technology with ACE BioSciences Protein Interaction Technology to validate the developed antibodies. Genmab and ACE BioSciences will collaborate on the research, development and commercialization of the new antibody products and will share equally development costs and revenues generated from out-licensing or sales of these products. "We are very happy to enter this alliance with ACE BioSciences which should enable us to develop human antibody products to treat patients suffering from infectious diseases," said Lisa N. Drakeman, Ph.D., Genmab's Chief Executive Officer. "This collaboration means we can continue to feed our bulging product pipeline and emphasizes Genmab's commitment to becoming a major player in the antibody therapeutics sector." "ACE BioSciences has established a powerful integrated biological and analytical chemistry platform to discover and validate targets in infectious diseases in a large scale and the collaboration with Genmab enables us to start the development of therapeutics to these targets," said Ejvind Mortz, Ph.D., ACE BioSciences' Chief Executive Officer. "We are very excited by this alliance with Genmab, because their expertise and proven track record in developing therapeutic antibodies positions ACE BioSciences on a fast track to develop treatments for infectious diseases." About Genmab Genmab A/S is a biotechnology company that creates and develops fully human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab's commercial opportunities are based upon research conducted at leading international companies, including Roche, Immunex Corporation, Oxford GlycoSciences Ltd., Medarex, Inc., deCODE Genetics, Scancell, Ltd., Sequenom, Inc., Eos Biotechnology Inc., Glaucus Proteomics B.V., Bionomics and Paradigm Therapeutics, as well as in its own laboratories. A broad alliance provides Genmab with access to Medarex Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of fully human antibodies to virtually any disease target. Genmab is headquartered in Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit genmab.com . About ACE BioSciences ACE BioSciences focus on infectious diseases and is based on a broad biotechnology platform integrating biology and analytical chemistry. The Protein Interaction Technology enables ACE BioSceiences to discover novel protein targets in a wide range of infectious bacteria and fungi. We collaborate with the biotechnology and pharmaceutical industries to improve our technology platform and use our validated targets to develop new therapeutics. ACE BioSciences has to date established alliances with Micromass (UK), LION bioscience (DE), Gyros (SE), the Statens Serum Institute (DK) and the University of Southern Denmark, Odense. ACE BioSciences is situated in Odense, Denmark. For more information visit acebiosciences.com